CVS 1123

Subscribe to Selected New Research on CVS 1123

2 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Description: a synthetic peptidomimetic

Also Known As:

(CH3CH2CH2)2-CH-CO-Asp(OCH3)-Pro-Arg-CHO; CVS-1123; alpha-propylpentanoyl-(OMe)aspartyl-prolyl-argininaldehyde

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Peptides: 16074

Oligopeptides: 165

CVS 1123: 2

Related Diseases

1.	Thrombosis (Thrombus) 02/01/1997 - "CVS-1123 administration was associated with a decrease in the thrombus weights in both the LCA and RJV as compared with the saline-treated animals" 10/01/1996 - "Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog." 10/01/1996 - "CONCLUSIONS: The direct thrombin inhibitor CVS-1123 is effective after oral administration in reducing the incidence of primary thrombus formation in an experimental model of arterial wall injury" 02/01/1997 - "CVS-1123, low-molecular-weight, direct thrombin inhibitor was studied in an anesthetized canine model of arterial and venous thrombosis to determine whether thrombin inhibition could reduce the incidence of occlusive thrombosis in response to vessel-wall injury" 10/01/1996 - "Thrombin-specific inhibitors, such as CVS-1123, may be alternative antithrombotic agents in clinical settings in which heparin-associated thrombosis is a complicating factor or when long-term anticoagulation is required." Get all the results and reference details, order at left...
2.	Venous Thrombosis (Deep-Vein Thrombosis) 02/01/1997 - "The results suggest that CVS-1123 is an effective antithrombin and may offer a therapeutic alternative to current antithrombins in the management of arterial and venous thrombosis." 02/01/1997 - "CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury." 02/01/1997 - "CVS-1123, low-molecular-weight, direct thrombin inhibitor was studied in an anesthetized canine model of arterial and venous thrombosis to determine whether thrombin inhibition could reduce the incidence of occlusive thrombosis in response to vessel-wall injury" Get all the results and reference details, order at left...
2 Diseases and 2 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Thrombin
2.	Heparin (Liquaemin)
3.	Fibrinolytic Agents (Antithrombotic Agents)
4.	Antithrombins
5.	glucuronyl glucosamine glycan sulfate (Vessel)
5 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>